Provided are compounds comprising a 9-membered ring to which four 6-membered carbocyclic or heterocyclic aromatic rings as well as one further 5-membered or 6-membered heterocyclic ring are fused. Also provided are formulations comprising these compounds. Further provided are organic light emitting devices (OLEDs) as well as related consumer products that utilize these compounds.

Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as oxaliplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, colorectal cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.

The present invention includes novel heterocyclic materials for use as blue phosphorescent materials in OLED devices. The materials are based on carbene and heterocyclic 5-membered ring linked ligands, which may be complexed to a transition metal via a metal-carbon (carbene) bond and a metal-nitrogen covalent bond. In one aspect, the present invention provides compounds comprising a ligand L.sub.A having the structure of Formula I: ##STR00001##

A method for synthesizing Pt(PF.sub.3).sub.4 (CAS # 19529-53-4) comprises dissolving a platinum compound having a general formula, Pt(Hal).sub.2(PF.sub.3).sub.x, in an anhydrous solvent forming a Pt(Hal).sub.2(PF.sub.3).sub.x solution, wherein Hal=F, Cl, Br or I, x=1, 2, adding a metal powder and excess amount of PF.sub.3 into the Pt(Hal).sub.2(PF.sub.3).sub.x solution, and forming Pt(PF.sub.3).sub.4 through a reaction between Pt(Hal).sub.2(PF.sub.3).sub.x, PF.sub.3 and the metal powder under a reaction condition. The method further comprises synthesizing Pt(Hal).sub.2(PF.sub.3).sub.xthrough the steps of dispersing a platinum precursor having a general formula, Pt(Hal).sub.2, into the anhydrous solvent forming a suspension of Pt(Hal).sub.2, wherein Hal=F, Cl, Br or I, introducing PF.sub.3 into the suspension of Pt(Hal).sub.2, and forming the solution of the platinum compound Pt(Hal).sub.2(PF.sub.3).sub.xin the anhydrous solvent through a reaction of PF.sub.3 and Pt(Hal).sub.2.

Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.

An organometallic compound and an organic light-emitting diode (OLED) including the organometallic compound are provided. In exemplary embodiments, the organometallic compound is a platinum complex comprising one or two heterocyclic ligands, the heterocyclic ligands being the same or different if they are two in number, each heterocyclic ligand comprising two nitrogen heterocyclic rings connected by a single bond, one of the rings being six membered and comprising at least one nitrogen and the other ring being a 1,2-diazole or a 1,2,4-triazole ring. One or two other organic ligands may be attached to the central platinum atom in the complex. OLEDs including one of the subject platinum compounds in a light emission layer exhibit lower driving voltages, higher luminances, higher efficiencies and longer lifetimes than do comparative OLEDs built with established dopants incorporated into the light emitting layers.

Bidentate heteroleptic square planar complexes of (pyridyl)azolates possess optical and electrical properties that render them useful for a wide variety of optical and electrical devices and applications. In particular, the complexes are useful for obtaining white or monochromatic organic light-emitting diodes (“OLEDs”), including doping-free OLEDs. Preferred forms also demonstrate semiconducting behavior and may be useful in a variety of other applications. Within the general complexes of (pyridyl)azolates, the metal and the ligands may be varied to impart different optoelectronic properties.

New derivatives of a Pt (II) complex provided which are liposoluble and useful as anticancer agents. Also disclosed are platinum II complexes in delivery systems such as liposomes, emulsions, nanoemulsions, and lipid excipients.

The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.

The invention relates to the use of compounds of formulae (I) and/or (II) as colorless IR absorbers wherein M is Ni, Pd, Pt, Au, Ir, Fe, Zn, W, Cu, Mo, In, Mn, Co, Mg, V, Cr or Ti, X.sub.1, X.sub.2 and X.sub.3 are each independently of the others sulfur or oxygen, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently of the others hydrogen, NR.sub.7R.sub.8, unsubstituted or substituted C.sub.1-C.sub.18alkyl, C.sub.1-C.sub.18 alkyl wherein the alkylene chain is interrupted with oxygen, unsubstituted or substituted C.sub.1-C.sub.18alkenyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl or unsubstituted or substituted heteroarylalkyl, R.sub.7 and R.sub.8, each independently of the other, being unsubstituted or substituted C.sub.1-C.sub.18alkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl or unsubstituted or substituted heteroarylalkyl, a further IR absorber optionally being added to the compounds of formulae (I) and (II). The invention relates also to novel dithiolene compounds of formulae (I) and (II) wherein X.sub.1 is oxygen and X.sub.2 and X.sub.3 are oxygen or sulfur. The invention relates furthermore to novel dithiolene compounds of formulae (I) and (II) wherein R.sub.1 to R.sub.6 are NR.sub.7R.sub.8. ##STR00001##